State-of-the-art document on optimal contemporary management of cardiomyopathies.
Aetiology
Arrhythmogenic cardiomyopathy
Dilated cardiomyopathy
Hypertrophic cardiomyopathy
Management
Mortality
Restrictive cardiomyopathy
Treatment
Journal
European journal of heart failure
ISSN: 1879-0844
Titre abrégé: Eur J Heart Fail
Pays: England
ID NLM: 100887595
Informations de publication
Date de publication:
Nov 2023
Nov 2023
Historique:
revised:
27
06
2023
received:
19
03
2023
accepted:
05
07
2023
pubmed:
20
7
2023
medline:
20
7
2023
entrez:
20
7
2023
Statut:
ppublish
Résumé
Cardiomyopathies represent significant contributors to cardiovascular morbidity and mortality. Over the past decades, a progress has occurred in characterization of the genetic background and major pathophysiological mechanisms, which has been incorporated into a more nuanced diagnostic approach and risk stratification. Furthermore, medications targeting core disease processes and/or their downstream adverse effects have been introduced for several cardiomyopathies. Combined with standard care and prevention of sudden cardiac death, these novel and emerging targeted therapies offer a possibility of improving the outcomes in several cardiomyopathies. Therefore, the aim of this document is to summarize practical approaches to the treatment of cardiomyopathies, which includes the evidence-based novel therapeutic concepts and established principles of care, tailored to the individual patient aetiology and clinical presentation of the cardiomyopathy. The scope of the document encompasses contemporary treatment of dilated, hypertrophic, restrictive and arrhythmogenic cardiomyopathy. It was based on an expert consensus reached at the Heart Failure Association online Workshop, held on 18 March 2021.
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1899-1922Informations de copyright
© 2023 European Society of Cardiology.
Références
McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). With the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2022;24:4-131. https://doi.org/10.1002/ejhf.2333
Seferović PM, Polovina M, Bauersachs J, Arad M, Ben Gal T, Lund LH, et al. Heart failure in cardiomyopathies: A position paper from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 2019;21:553-576. https://doi.org/10.1002/ejhf.1461
Merlo M, Cannatà A, Pio Loco C, Stolfo D, Barbati G, Artico J, et al. Contemporary survival trends and aetiological characterization in non-ischaemic dilated cardiomyopathy. Eur J Heart Fail 2020;22:1111-1121. https://doi.org/10.1002/ejhf.1914
de Boer RA, Heymans S, Backs J, Carrier L, Coats AJS, Dimmeler S, et al. Targeted therapies in genetic dilated and hypertrophic cardiomyopathies: From molecular mechanisms to therapeutic targets. A position paper from the Heart Failure Association (HFA) and the Working Group on Myocardial Function of the European Society of Cardiology (ESC). Eur J Heart Fail 2022;24:406-420. https://doi.org/10.1002/ejhf.2414
Pinto YM, Elliott PM, Arbustini E, Adler Y, Anastasakis A, Böhm M, et al. Proposal for a revised definition of dilated cardiomyopathy, hypokinetic non-dilated cardiomyopathy, and its implications for clinical practice: A position statement of the ESC working group on myocardial and pericardial diseases. Eur Heart J 2016;37:1850-1858. https://doi.org/10.1093/eurheartj/ehv727
van Rijsingen IAW, Arbustini E, Elliott PM, Mogensen J, Hermans-van Ast JF, van der Kooi AJ, et al. Risk factors for malignant ventricular arrhythmias in lamin A/C mutation carriers: A European cohort study. J Am Coll Cardiol 2012;59:493-500. https://doi.org/10.1016/j.jacc.2011.08.078
Paulus WJ, Zile MR. From systemic inflammation to myocardial fibrosis: The heart failure with preserved ejection fraction paradigm revisited. Circ Res 2021;128:1451-1467. https://doi.org/10.1161/CIRCRESAHA.121.318159
Rosenbaum AN, Agre KE, Pereira NL. Genetics of dilated cardiomyopathy: Practical implications for heart failure management. Nat Rev Cardiol 2020;17:286-297. https://doi.org/10.1038/s41569-019-0284-0
Kayvanpour E, Sedaghat-Hamedani F, Amr A, Lai A, Haas J, Holzer DB, et al. Genotype-phenotype associations in dilated cardiomyopathy: Meta-analysis on more than 8000 individuals. Clin Res Cardiol 2017;106:127-139. https://doi.org/10.1007/s00392-016-1033-6
Lewis GA, Schelbert EB, Williams SG, Cunnington C, Ahmed F, McDonagh TA, et al. Biological phenotypes of heart failure with preserved ejection fraction. J Am Coll Cardiol 2017;70:2186-2200. https://doi.org/10.1016/j.jacc.2017.09.006
Hazebroek MR, Moors S, Dennert R, van den Wijngaard A, Krapels I, Hoos M, et al. Prognostic relevance of gene-environment interactions in patients with dilated cardiomyopathy: Applying the MOGE(S) classification. J Am Coll Cardiol 2015;66:1313-1323. https://doi.org/10.1016/j.jacc.2015.07.023
Verdonschot JAJ, Hazebroek MR, Wang P, Sanders-van Wijk S, Merken JJ, Adriaansen YA, et al. Clinical phenotype and genotype associations with improvement in left ventricular function in dilated cardiomyopathy. Circ Heart Fail 2018;11:e005220. https://doi.org/10.1161/CIRCHEARTFAILURE.118.005220
Henkens M, Stroeks S, Raafs AG, Sikking MA, Tromp J, Ouwerkerk W, et al. Dynamic ejection fraction trajectory in patients with dilated cardiomyopathy with a truncating titin variant. Circ Heart Fail 2022;15:e009352. https://doi.org/10.1161/CIRCHEARTFAILURE.121.009352
Escobar-Lopez L, Ochoa JP, Royuela A, Verdonschot JAJ, Ferro MD, Espinosa MA, et al. Clinical risk score to predict pathogenic genotypes in patients with dilated cardiomyopathy. J Am Coll Cardiol 2022;80:1115-1126. https://doi.org/10.1016/j.jacc.2022.06.040
Wahbi K, Yaou RB, Gandjbakhch E, Anselme F, Gossios T, Lakdawala NK, et al. Development and validation of a new risk prediction score for life-threatening ventricular tachyarrhythmias in laminopathies. Circulation 2019;140:293-302. https://doi.org/10.1161/CIRCULATIONAHA.118.039410
Ammirati E, Moslehi JJ. Diagnosis and treatment of acute myocarditis: A review. JAMA 2023;329:1098-1113. https://doi.org/10.1001/jama.2023.3371
Keinath K, Church T, Kurth B, Hulten E. Myocarditis secondary to smallpox vaccination. BMJ Case Rep 2018;2018:bcr2017223523. https://doi.org/10.1136/bcr-2017-223523
Wang WH, Wei KC, Huang YT, Huang KH, Tsai TH, Chang YC. The incidence of myocarditis following an influenza vaccination: A population-based observational study. Drugs Aging 2023;40:145-151. https://doi.org/10.1007/s40266-022-00997-0
Lota AS, Hazebroek MR, Theotokis P, Wassall R, Salmi S, Halliday BP, et al. Genetic architecture of acute myocarditis and the overlap with inherited cardiomyopathy. Circulation 2022;146:1123-1134. https://doi.org/10.1161/CIRCULATIONAHA.121.058457
Seferović PM, Tsutsui H, McNamara DM, Ristić AD, Basso C, Bozkurt B, et al. Heart Failure Association of the ESC, Heart Failure Society of America and Japanese Heart Failure Society Position statement on endomyocardial biopsy. Eur J Heart Fail 2021;23:854-871. https://doi.org/10.1002/ejhf.2190
Ammirati E, Frigerio M, Adler ED, Basso C, Birnie DH, Brambatti M, et al. Management of acute myocarditis and chronic inflammatory cardiomyopathy: An expert consensus document. Circ Heart Fail 2020;13:e007405. https://doi.org/10.1161/CIRCHEARTFAILURE.120.007405
Cooper LT Jr, Hare JM, Tazelaar HD, Edwards WD, Starling RC, Deng MC, et al. Usefulness of immunosuppression for giant cell myocarditis. Am J Cardiol 2008;102:1535-1539. https://doi.org/10.1016/j.amjcard.2008.07.041
Brambatti M, Matassini MV, Adler ED, Klingel K, Camici PG, Ammirati E. Eosinophilic myocarditis: Characteristics, treatment, and outcomes. J Am Coll Cardiol 2017;70:2363-2375. https://doi.org/10.1016/j.jacc.2017.09.023
Zotova L. Immune checkpoint inhibitors-related myocarditis: A review of reported clinical cases. Diagnostics (Basel) 2023;13:1243. https://doi.org/10.3390/diagnostics13071243
Turgeon PY, Massot M, Beaupré F, Belzile D, Beaudoin J, Bernier M, et al. Effect of acute immunosuppression on left ventricular recovery and mortality in fulminant viral myocarditis: A case series and review of literature. CJC Open 2021;3:292-302. https://doi.org/10.1016/j.cjco.2020.10.017
Pelliccia A, Sharma S, Gati S, Bäck M, Börjesson M, Caselli S, et al. 2020 ESC Guidelines on sports cardiology and exercise in patients with cardiovascular disease. Eur Heart J 2021;42:17-96. https://doi.org/10.1093/eurheartj/ehaa605
Mason JW, O'Connell JB, Herskowitz A, Rose NR, McManus BM, Billingham ME, et al. A clinical trial of immunosuppressive therapy for myocarditis. The Myocarditis Treatment Trial Investigators. N Engl J Med 1995;333:269-275. https://doi.org/10.1056/NEJM199508033330501
Wojnicz R, Nowalany-Kozielska E, Wojciechowska C, Glanowska G, Wilczewski P, Niklewski T, et al. Randomized, placebo-controlled study for immunosuppressive treatment of inflammatory dilated cardiomyopathy. Circulation 2001;104:39-45. https://doi.org/10.1161/01.cir.104.1.39
Frustaci A, Russo MA, Chimenti C. Randomized study on the efficacy of immunosuppressive therapy in patients with virus-negative inflammatory cardiomyopathy: The TIMIC study. Eur Heart J 2009;30:1995-2002. https://doi.org/10.1093/eurheartj/ehp249
Chimenti C, Russo MA, Frustaci A. Immunosuppressive therapy in virus-negative inflammatory cardiomyopathy: 20-year follow-up of the TIMIC trial. Eur Heart J 2022;43:3463-3473. https://doi.org/10.1093/eurheartj/ehac348
Merken J, Hazebroek M, Van Paassen P, Verdonschot J, Van Empel V, Knackstedt C, et al. Immunosuppressive therapy improves both short- and long-term prognosis in patients with virus-negative nonfulminant inflammatory cardiomyopathy. Circ Heart Fail 2018;11:e004228. https://doi.org/10.1161/CIRCHEARTFAILURE.117.004228
Tschöpe C, Elsanhoury A, Schlieker S, Van Linthout S, Kühl U. Immunosuppression in inflammatory cardiomyopathy and parvovirus B19 persistence. Eur J Heart Fail 2019;21:1468-1469. https://doi.org/10.1002/ejhf.1560
Schultheiss HP, Piper C, Sowade O, Waagstein F, Kapp JF, Wegscheider K, et al. Betaferon in chronic viral cardiomyopathy (BICC) trial: Effects of interferon-β treatment in patients with chronic viral cardiomyopathy. Clin Res Cardiol 2016;105:763-773. https://doi.org/10.1007/s00392-016-0986-9
Felix SB, Staudt A, Dörffel WV, Stangl V, Merkel K, Pohl M, et al. Hemodynamic effects of immunoadsorption and subsequent immunoglobulin substitution in dilated cardiomyopathy: Three-month results from a randomized study. J Am Coll Cardiol 2000;35:1590-1598. https://doi.org/10.1016/s0735-1097(00)00568-4
Ohlow MA, Brunelli M, Schreiber M, Lauer B. Therapeutic effect of immunoadsorption and subsequent immunoglobulin substitution in patients with dilated cardiomyopathy: Results from the observational prospective Bad Berka Registry. J Cardiol 2017;69:409-416. https://doi.org/10.1016/j.jjcc.2016.07.014
Sliwa K, Bauersachs J, Arany Z, Spracklen TF, Hilfiker-Kleiner D. Peripartum cardiomyopathy: From genetics to management. Eur Heart J 2021;42:3094-3102. https://doi.org/10.1093/eurheartj/ehab458
Bauersachs J, König T, van der Meer P, Petrie MC, Hilfiker-Kleiner D, Mbakwem A, et al. Pathophysiology, diagnosis and management of peripartum cardiomyopathy: A position statement from the Heart Failure Association of the European Society of Cardiology Study Group on peripartum cardiomyopathy. Eur J Heart Fail 2019;21:827-843. https://doi.org/10.1002/ejhf.1493
Kryczka KE, Dzielińska Z, Franaszczyk M, Wojtkowska I, Henzel J, Śpiewak M, et al. Severe course of peripartum cardiomyopathy and subsequent recovery in a patient with a novel TTN gene-truncating mutation. Am J Case Rep 2018;19:820-824. https://doi.org/10.12659/AJCR.909601
Spracklen TF, Chakafana G, Schwartz PJ, Kotta MC, Shaboodien G, Ntusi NAB, et al. Genetics of peripartum cardiomyopathy: Current knowledge, future directions and clinical implications. Genes (Basel) 2021;12:103. https://doi.org/10.3390/genes12010103
Sliwa K, Petrie MC, van der Meer P, Mebazaa A, Hilfiker-Kleiner D, Jackson AM, et al. Clinical presentation, management, and 6-month outcomes in women with peripartum cardiomyopathy: An ESC EORP registry. Eur Heart J 2020;41:3787-3797. https://doi.org/10.1093/eurheartj/ehaa455
Bauersachs J, Arrigo M, Hilfiker-Kleiner D, Veltmann C, Coats AJ, Crespo-Leiro MG, et al. Current management of patients with severe acute peripartum cardiomyopathy: Practical guidance from the Heart Failure Association of the European Society of Cardiology Study Group on peripartum cardiomyopathy. Eur J Heart Fail 2016;18:1096-1105. https://doi.org/10.1002/ejhf.586
Stapel B, Kohlhaas M, Ricke-Hoch M, Haghikia A, Erschow S, Knuuti J, et al. Low STAT3 expression sensitizes to toxic effects of β-adrenergic receptor stimulation in peripartum cardiomyopathy. Eur Heart J 2017;38:349-361. https://doi.org/10.1093/eurheartj/ehw086
Biteker M, Duran NE, Kaya H, Gündüz S, Tanboğa H, Gökdeniz T, et al. Effect of levosimendan and predictors of recovery in patients with peripartum cardiomyopathy, a randomized clinical trial. Clin Res Cardiol 2011;100:571-577. https://doi.org/10.1007/s00392-010-0279-7
Abdel Hamid H, El-Tohamy S. Comparison between milrinone and levosimendan infusion in patients with peripartum cardiomyopathy. Ain Shams J Anaesthesiol 2014;7:114-120. https://doi.org/10.4103/1687-7934.133308
Sieweke JT, Pfeffer TJ, Berliner D, König T, Hallbaum M, Napp LC, et al. Cardiogenic shock complicating peripartum cardiomyopathy: Importance of early left ventricular unloading and bromocriptine therapy. Eur Heart J Acute Cardiovasc Care 2020;9:173-182. https://doi.org/10.1177/2048872618777876
Berliner D, Li T, Mariani S, Hamdan R, Hanke J, König T, et al. Clinical characteristics and long-term outcomes in patients with peripartum cardiomyopathy (PPCM) receiving left ventricular assist devices (LVAD). Artif Organs 2023;47:417-424. https://doi.org/10.1111/aor.14406
Ricke-Hoch M, Pfeffer TJ, Hilfiker-Kleiner D. Peripartum cardiomyopathy: Basic mechanisms and hope for new therapies. Cardiovasc Res 2020;116:520-531. https://doi.org/10.1093/cvr/cvz252
Hilfiker-Kleiner D, Haghikia A, Berliner D, Vogel-Claussen J, Schwab J, Franke A, et al. Bromocriptine for the treatment of peripartum cardiomyopathy: A multicentre randomized study. Eur Heart J 2017;38:2671-2679. https://doi.org/10.1093/eurheartj/ehx355
Regitz-Zagrosek V, Roos-Hesselink JW, Bauersachs J, Blomström-Lundqvist C, Cífková R, De Bonis M, et al. 2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy. Eur Heart J 2018;39:3165-3241. https://doi.org/10.1093/eurheartj/ehy340
Haghikia A, Schwab J, Vogel-Claussen J, Berliner D, Pfeffer T, König T, et al. Bromocriptine treatment in patients with peripartum cardiomyopathy and right ventricular dysfunction. Clin Res Cardiol 2019;108:290-297. https://doi.org/10.1007/s00392-018-1355-7
Elkayam U. Risk of subsequent pregnancy in women with a history of peripartum cardiomyopathy. J Am Coll Cardiol 2014;64:1629-1636. https://doi.org/10.1016/j.jacc.2014.07.961
Lyon AR, López-Fernández T, Couch LS, Asteggiano R, Aznar MC, Bergler-Klein J, et al.; ESC Scientific Document Group. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J 2022;43:4229-4361. https://doi.org/10.1093/eurheartj/ehac244
López-Sendón J, Álvarez-Ortega C, Zamora Auñon P, Buño Soto A, Lyon AR, Farmakis D, et al. Classification, prevalence, and outcomes of anticancer therapy-induced cardiotoxicity: The CARDIOTOX registry. Eur Heart J 2020;41:1720-1729. https://doi.org/10.1093/eurheartj/ehaa006
Farmakis D, Mantzourani M, Filippatos G. Anthracycline-induced cardiomyopathy: Secrets and lies. Eur J Heart Fail 2018;20:907-909. https://doi.org/10.1002/ejhf.1172
Cardinale D, Colombo A, Lamantia G, Colombo N, Civelli M, De Giacomi G, et al. Anthracycline-induced cardiomyopathy: Clinical relevance and response to pharmacologic therapy. J Am Coll Cardiol 2010;55:213-220. https://doi.org/10.1016/j.jacc.2009.03.095
Lyon AR, Dent S, Stanway S, Earl H, Brezden-Masley C, Cohen-Solal A, et al. Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: A position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society. Eur J Heart Fail 2020;22:1945-1960. https://doi.org/10.1002/ejhf.1920
Čelutkienė J, Pudil R, López-Fernández T, Grapsa J, Nihoyannopoulos P, Bergler-Klein J, et al. Role of cardiovascular imaging in cancer patients receiving cardiotoxic therapies: A position statement on behalf of the Heart Failure Association (HFA), the European Association of Cardiovascular Imaging (EACVI) and the Cardio-Oncology Council of the European Society of Cardiology (ESC). Eur J Heart Fail 2020;22:1504-1524. https://doi.org/10.1002/ejhf.1957
Pudil R, Mueller C, Čelutkienė J, Henriksen PA, Lenihan D, Dent S, et al. Role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies: A position statement from the Cardio-Oncology Study Group of the Heart Failure Association and the Cardio-Oncology Council of the European Society of Cardiology. Eur J Heart Fail 2020;22:1966-1983. https://doi.org/10.1002/ejhf.2017
Brahmer JR, Abu-Sbeih H, Ascierto PA, Brufsky J, Cappelli LC, Cortazar FB, et al. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events. J Immunother Cancer 2021;9:e002435. https://doi.org/10.1136/jitc-2021-002435
Zhang L, Zlotoff DA, Awadalla M, Mahmood SS, Nohria A, Hassan MZO, et al. Major adverse cardiovascular events and the timing and dose of corticosteroids in immune checkpoint inhibitor-associated myocarditis. Circulation 2020;141:2031-2034. https://doi.org/10.1161/CIRCULATIONAHA.119.044703
Arangalage D, Delyon J, Lermuzeaux M, Ekpe K, Ederhy S, Pages C, et al. Survival after fulminant myocarditis induced by immune-checkpoint inhibitors. Ann Intern Med 2017;167:683-684. https://doi.org/10.7326/L17-0396
Salem JE, Allenbach Y, Vozy A, Brechot N, Johnson DB, Moslehi JJ, et al. Abatacept for severe immune checkpoint inhibitor-associated myocarditis. N Engl J Med 2019;380:2377-2379. https://doi.org/10.1056/NEJMc1901677
Esfahani K, Buhlaiga N, Thébault P, Lapointe R, Johnson NA, Miller WH Jr. Alemtuzumab for immune-related myocarditis due to PD-1 therapy. N Engl J Med 2019;380:2375-2376. https://doi.org/10.1056/NEJMc1903064
Roth ME, Muluneh B, Jensen BC, Madamanchi C, Lee CB. Left ventricular dysfunction after treatment with ipilimumab for metastatic melanoma. Am J Ther 2016;23:e1925-e1928. https://doi.org/10.1097/MJT.0000000000000430
Cardinale D, Ciceri F, Latini R, Franzosi MG, Sandri MT, Civelli M, et al. Anthracycline-induced cardiotoxicity: A multicenter randomised trial comparing two strategies for guiding prevention with enalapril: The International CardioOncology Society-one trial. Eur J Cancer 2018;94:126-137. https://doi.org/10.1016/j.ejca.2018.02.005
Thavendiranathan P, Negishi T, Somerset E, Negishi K, Penicka M, Lemieux J, et al. Strain-guided management of potentially cardiotoxic cancer therapy. J Am Coll Cardiol 2021;77:392-401. https://doi.org/10.1016/j.jacc.2020.11.020
Cardinale D, Colombo A, Bacchiani G, Tedeschi I, Meroni CA, Veglia F, et al. Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy. Circulation 2015;131:1981-1988. https://doi.org/10.1161/CIRCULATIONAHA.114.013777
Quagliariello V, De Laurentiis M, Rea D, Barbieri A, Monti MG, Carbone A, et al. The SGLT-2 inhibitor empagliflozin improves myocardial strain, reduces cardiac fibrosis and pro-inflammatory cytokines in non-diabetic mice treated with doxorubicin. Cardiovasc Diabetol 2021;20:150. https://doi.org/10.1186/s12933-021-01346-y
Martín-Garcia A, López-Fernández T, Mitroi C, Chaparro-Muñoz M, Moliner P, Martin-Garcia AC, et al. Effectiveness of sacubitril-valsartan in cancer patients with heart failure. ESC Heart Fail 2020;7:763-767. https://doi.org/10.1002/ehf2.12627
Frey MK, Arfsten H, Pavo N, Han E, Kastl S, Hülsmann M, et al. Sacubitril/valsartan is well tolerated in patients with longstanding heart failure and history of cancer and improves ventricular function: Real-world data. Cardiooncology 2021;7:35. https://doi.org/10.1186/s40959-021-00121-y
Fragasso G, Sanvito F, Baratto F, Martinenghi S, Doglioni C, Margonato A. Cardiotoxicity after low-dose chloroquine antimalarial therapy. Heart Vessels 2009;24:385-387. https://doi.org/10.1007/s00380-008-1144-8
Costedoat-Chalumeau N, Hulot JS, Amoura Z, Delcourt A, Maisonobe T, Dorent R, et al. Cardiomyopathy related to antimalarial therapy with illustrative case report. Cardiology 2006;107:73-80. https://doi.org/10.1159/000094079
Page RL, O'Bryant CL, Cheng D, Dow TJ, Ky B, Stein CM, et al. Drugs that may cause or exacerbate heart failure. Circulation 2016;134:e32-e69. https://doi.org/10.1161/CIR.0000000000000426
Volkov VP. Antipsychotic cardiomyopathy: To the problem of clinical diagnosis. MOJ Toxicol 2018;4:238-240. https://doi.org/10.15406/mojt.2018.04.00106
Ronaldson KJ, Taylor AJ, Fitzgerald PB, Topliss DJ, Elsik M, McNeil JJ. Diagnostic characteristics of clozapine-induced myocarditis identified by an analysis of 38 cases and 47 controls. J Clin Psychiatry 2010;71:976-981. https://doi.org/10.4088/JCP.09m05024yel
Aichhorn W, Huber R, Stuppaeck C, Whitworth AB. Cardiomyopathy after long-term treatment with lithium - more than a coincidence? J Psychopharmacol 2006;20:589-591. https://doi.org/10.1177/0269881106059696
Huizar JF, Ellenbogen KA, Tan AY, Kaszala K. Arrhythmia-induced cardiomyopathy: JACC state-of-the-art review. J Am Coll Cardiol 2019;73:2328-2344. https://doi.org/10.1016/j.jacc.2019.02.045
Baman TS, Lange DC, Ilg KJ, Gupta SK, Liu TY, Alguire C, et al. Relationship between burden of premature ventricular complexes and left ventricular function. Heart Rhythm 2010;7:865-869. https://doi.org/10.1016/j.hrthm.2010.03.036
Prinzen FW, Auricchio A, Mullens W, Linde C, Huizar JF. Electrical management of heart failure: From pathophysiology to treatment. Eur Heart J 2022;43:1917-1927. https://doi.org/10.1093/eurheartj/ehac088
Shelton RJ, Clark AL, Goode K, Rigby AS, Houghton T, Kaye GC, et al. A randomised, controlled study of rate versus rhythm control in patients with chronic atrial fibrillation and heart failure: (CAFE-II Study). Heart 2009;95:924-930. https://doi.org/10.1136/hrt.2008.158931
Di Biase L, Mohanty P, Mohanty S, Santangeli P, Trivedi C, Lakkireddy D, et al. Ablation versus amiodarone for treatment of persistent atrial fibrillation in patients with congestive heart failure and an implanted device: Results from the AATAC multicenter randomized trial. Circulation 2016;133:1637-1644. https://doi.org/10.1161/CIRCULATIONAHA.115.019406
Marrouche NF, Brachmann J, Andresen D, Siebels J, Boersma L, Jordaens L, et al.; CASTLE-AF Investigators. Catheter ablation for atrial fibrillation with heart failure. N Engl J Med 2018;378:417-427. https://doi.org/10.1056/NEJMoa1707855
Takemoto M, Yoshimura H, Ohba Y, Matsumoto Y, Yamamoto U, Mohri M, et al. Radiofrequency catheter ablation of premature ventricular complexes from right ventricular outflow tract improves left ventricular dilation and clinical status in patients without structural heart disease. J Am Coll Cardiol 2005;45:1259-1265. https://doi.org/10.1016/j.jacc.2004.12.073
Watanabe H, Okamura K, Chinushi M, Furushima H, Tanabe Y, Kodama M, et al. Clinical characteristics, treatment, and outcome of tachycardia induced cardiomyopathy. Int Heart J 2008;49:39-47. https://doi.org/10.1536/ihj.49.39
Nerheim P, Birger-Botkin S, Piracha L, Olshansky B. Heart failure and sudden death in patients with tachycardia-induced cardiomyopathy and recurrent tachycardia. Circulation 2004;110:247-252. https://doi.org/10.1161/01.CIR.0000135472.28234.CC
Wood AM, Kaptoge S, Butterworth AS, Willeit P, Warnakula S, Bolton T, et al.; Emerging Risk Factors Collaboration/EPIC-CVD/UK Biobank Alcohol Study Group. Risk thresholds for alcohol consumption: Combined analysis of individual-participant data for 599 912 current drinkers in 83 prospective studies. Lancet 2018;391:1513-1523. https://doi.org/10.1016/S0140-6736(18)30134-X
Andersson C, Schou M, Gustafsson F, Torp-Pedersen C. Alcohol intake in patients with cardiomyopathy and heart failure: Consensus and controversy. Circ Heart Fail 2022;15:e009459. https://doi.org/10.1161/CIRCHEARTFAILURE.121.009459
Guzzo-Merello G, Segovia J, Dominguez F, Cobo-Marcos M, Gomez-Bueno M, Avellana P, et al. Natural history and prognostic factors in alcoholic cardiomyopathy. JACC Heart Fail 2015;3:78-86. https://doi.org/10.1016/j.jchf.2014.07.014
Prazak P, Pfisterer M, Osswald S, Buser P, Burkart F. Differences of disease progression in congestive heart failure due to alcoholic as compared to idiopathic dilated cardiomyopathy. Eur Heart J 1996;17:251-257. https://doi.org/10.1093/oxfordjournals.eurheartj.a014842
Bozkurt B, Colvin M, Cook J, Cooper LT, Deswal A, Fonarow GC, et al. Current diagnostic and treatment strategies for specific dilated cardiomyopathies: A scientific statement from the American Heart Association. Circulation 2016;134:e579-e646. https://doi.org/10.1161/CIR.0000000000000455
Sliman S, Waalen J, Shaw D. Methamphetamine-associated congestive heart failure: Increasing prevalence and relationship of clinical outcomes to continued use or abstinence. Cardiovasc Toxicol 2016;16:381-389. https://doi.org/10.1007/s12012-015-9350-y
Remick J, Georgiopoulou V, Marti C, Ofotokun I, Kalogeropoulos A, Lewis W, et al. Heart failure in patients with human immunodeficiency virus infection. Circulation 2014;129:1781-1789. https://doi.org/10.1161/CIRCULATIONAHA.113.004574
Cerrato E, D'Ascenzo F, Biondi-Zoccai G, Calcagno A, Frea S, Grosso Marra W, et al. Cardiac dysfunction in pauci symptomatic human immunodeficiency virus patients: A meta-analysis in the highly active antiretroviral therapy era. Eur Heart J 2013;34:1432-1436. https://doi.org/10.1093/eurheartj/ehs471
Crum NF, Riffenburgh RH, Wegner S, Agan BK, Tasker SA, Spooner KM, et al. Comparisons of causes of death and mortality rates among HIV-infected persons: Analysis of the pre-, early, and late HAART (highly active antiretroviral therapy) eras. J Acquir Immune Defic Syndr 2006;41:194-200. https://doi.org/10.1097/01.qai.0000179459.31562.16
Lewis W. Cardiomyopathy in AIDS: A pathophysiological perspective. Prog Cardiovasc Dis 2000;43:151-170. https://doi.org/10.1053/pcad.2000.9031
Sabin CA, Worm SW, Weber R, Reiss P, El-Sadr W, Dabis F, et al. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: A multi-cohort collaboration. Lancet 2008;371:1417-1426. https://doi.org/10.1016/S0140-6736(08)60423-7
Castel MA, Pérez-Villa F, Miró JM. Heart transplantation in HIV-infected patients: More cases in Europe. J Heart Lung Transplant 2011;30:1418. https://doi.org/10.1016/j.healun.2011.07.022
Crespo-Leiro MG, Metra M, Lund LH, Milicic D, Costanzo MR, Filippatos G, et al. Advanced heart failure: A position statement of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 2018;20:1505-1535. https://doi.org/10.1002/ejhf.1236
Birk SE, Campbell R, Herre J, Baran DA, Yehya A. Clinical outcomes and survival of HIV positive and negative patients on LVAD support. J Heart Lung Transplant 2022;41:S121 (abstr). https://doi.org/10.1016/j.healun.2022.01.283
Viljoen CA, Hoevelmann J, Muller E, Sliwa K. Neglected cardiovascular diseases and their significance in the Global North. Herz 2021;46:129-137. https://doi.org/10.1007/s00059-021-05020-7
Nunes MC, Dones W, Morillo CA, Encina JJ, Ribeiro AL. Chagas disease: An overview of clinical and epidemiological aspects. J Am Coll Cardiol 2013;62:767-776. https://doi.org/10.1016/j.jacc.2013.05.046
Marin-Neto JA, Cunha-Neto E, Maciel BC, Simões MV. Pathogenesis of chronic Chagas heart disease. Circulation 2007;115:1109-1123. https://doi.org/10.1161/CIRCULATIONAHA.106.624296
Nunes MCP, Beaton A, Acquatella H, Bern C, Bolger AF, Echeverría LE, et al.; American Heart Association Rheumatic Fever, Endocarditis and Kawasaki Disease Committee of the Council on Cardiovascular Disease in the Young; Council on Cardiovascular and Stroke Nursing; and Stroke Council. Chagas cardiomyopathy: An update of current clinical knowledge and management: A scientific statement from the American Heart Association. Circulation 2018;138:e169-e209. https://doi.org/10.1161/CIR.0000000000000599
Morillo CA, Marin-Neto JA, Avezum A, Sosa-Estani S, Rassi A, Rosas F, et al.; BENEFIT Investigators. Randomized trial of benznidazole for chronic Chagas' cardiomyopathy. N Engl J Med 2015;373:1295-1306. https://doi.org/10.1056/NEJMoa1507574
Gray EB, La Hoz RM, Green JS, Vikram HR, Benedict T, Rivera H, et al. Reactivation of Chagas disease among heart transplant recipients in the United States, 2012-2016. Transpl Infect Dis 2018;20:e12996. https://doi.org/10.1111/tid.12996
Santos ES, Silva DKC, Dos Reis B, Barreto BC, Cardoso CMA, Ribeiro Dos Santos R, et al. Immunomodulation for the treatment of chronic Chagas disease cardiomyopathy: A new approach to an old enemy. Front Cell Infect Microbiol 2021;11:765879. https://doi.org/10.3389/fcimb.2021.765879
Bartůnek P, Gorican K, Mrázek V, Varejka P, Veiser T, Hercogová J, Hulínská D, Janovská D Lyme borreliosis infection as a cause of dilated cardiomyopathy. Prague Med Rep 2006;107(2):213-26. PMID: 17066741.
Kuchynka P, Palecek T, Havranek S, Vitkova I, Nemecek E, Trckova R, et al. Recent-onset dilated cardiomyopathy associated with Borrelia burgdorferi infection. Herz 2015;40:892-897. https://doi.org/10.1007/s00059-015-4308-1
Boldery R, Fielding G, Rafter T, Pascoe AL, Scalia GM. Nutritional deficiency of selenium secondary to weight loss (bariatric) surgery associated with life-threatening cardiomyopathy. Heart Lung Circ 2007;16:123-126. https://doi.org/10.1016/j.hlc.2006.07.013
Hunter L, Ferguson R, McDevitt H. Vitamin D deficiency cardiomyopathy in Scotland: A retrospective review of the last decade. Arch Dis Child 2020;105:853-856. https://doi.org/10.1136/archdischild-2019-317794
Paulson DJ. Carnitine deficiency-induced cardiomyopathy. Mol Cell Biochem 1998;180:33-41. https://doi.org/10.1023/A:1006826620218
Smith TJ, Johnson CR, Koshy R, Hess SY, Qureshi UA, Mynak ML, et al. Thiamine deficiency disorders: A clinical perspective. Ann N Y Acad Sci 2021;1498:9-28. https://doi.org/10.1111/nyas.14536
Liu Y, Miao J. An emerging role of defective copper metabolism in heart disease. Nutrients 2022;14:700. https://doi.org/10.3390/nu14030700
Ghadri J-R, Wittstein IS, Prasad A, Sharkey S, Dote K, Akashi YJ, et al. International expert consensus document on Takotsubo syndrome (Part I): Clinical characteristics, diagnostic criteria, and pathophysiology. Eur Heart J 2018;39:2032-2046. https://doi.org/10.1093/eurheartj/ehy076
Lee M. Time course of functional recovery in Takotsubo (stress) cardiomyopathy: A serial speckle tracking echocardiography and electrocardiography study. J Cardiovasc Imaging 2020;28:50-60. https://doi.org/10.4250/jcvi.2019.0083
Templin C, Ghadri JR, Diekmann J, Napp LC, Bataiosu DR, Jaguszewski M, et al. Clinical features and outcomes of Takotsubo (stress) cardiomyopathy. N Engl J Med 2015;373:929-938. https://doi.org/10.1056/NEJMoa1406761
Ghadri JR, Wittstein IS, Prasad A, Sharkey S, Dote K, Akashi YJ, et al. International expert consensus document on Takotsubo syndrome (Part II): Diagnostic workup, outcome, and management. Eur Heart J 2018;39:2047-2062. https://doi.org/10.1093/eurheartj/ehy077
Germain DP, Hughes DA, Nicholls K, Bichet DG, Giugliani R, Wilcox WR, et al. Treatment of Fabry's disease with the pharmacologic chaperone migalastat. N Engl J Med 2016;375:545-555. https://doi.org/10.1056/NEJMoa1510198
Jaguszewski MJ, Gasecka A, Hering D, Filipiak KJ, Szarpak L, Fijałkowski M, et al. Levosimendan improves the acute course of takotsubo syndrome: A pooled analysis. ESC Heart Fail 2021;8:4360-4363. https://doi.org/10.1002/ehf2.13486
Doucet KM, Labinaz MX, Beauchesne LM, Burwash IG. Cardiogenic shock in Takotsubo cardiomyopathy: A focus on management. Can J Cardiol 2015;31:84-87. https://doi.org/10.1016/j.cjca.2014.09.025
Napp LC, Westenfeld R, Møller JE, Pappalardo F, Ibrahim K, Bonello L, et al. Impella mechanical circulatory support for Takotsubo syndrome with shock: A retrospective multicenter analysis. Cardiovasc Revasc Med 2022;40:113-119. https://doi.org/10.1016/j.carrev.2021.11.018
Vece DD, Citro R, Cammann VL, Kato K, Gili S, Szawan KA, et al. Outcomes associated with cardiogenic shock in Takotsubo syndrome. Circulation 2019;139:413-415. https://doi.org/10.1161/CIRCULATIONAHA.118.036164
Lau C, Chiu S, Nayak R, Lin B, Lee MS. Survival and risk of recurrence of takotsubo syndrome. Heart 2021;107:1160-1166. https://doi.org/10.1136/heartjnl-2020-318028
Elliott PM, Anastasakis A, Borger MA, Borggrefe M, Cecchi F, Charron P, et al. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: The Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J 2014;35:2733-2779. https://doi.org/10.1093/eurheartj/ehu284
Elliott P, Andersson B, Arbustini E, Bilinska Z, Cecchi F, Charron P, et al. Classification of the cardiomyopathies: A position statement from the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J 2008;29:270-276. https://doi.org/10.1093/eurheartj/ehm342
Marian AJ. Molecular genetic basis of hypertrophic cardiomyopathy. Circ Res 2021;128:1533-1553. https://doi.org/10.1161/CIRCRESAHA.121.318346
Bonaventura J, Polakova E, Vejtasova V, Veselka J. Genetic testing in patients with hypertrophic cardiomyopathy. Int J Mol Sci 2021;22:10401. https://doi.org/10.3390/ijms221910401
Mathew J, Zahavich L, Lafreniere-Roula M, Wilson J, George K, Benson L, et al. Utility of genetics for risk stratification in pediatric hypertrophic cardiomyopathy. Clin Genet 2018;93:310-319. https://doi.org/10.1111/cge.13157
van Velzen HG, Vriesendorp PA, Oldenburg RA, van Slegtenhorst MA, van der Velden J, Schinkel AFL, et al. Value of genetic testing for the prediction of long-term outcome in patients with hypertrophic cardiomyopathy. Am J Cardiol 2016;118:881-887. https://doi.org/10.1016/j.amjcard.2016.06.038
Ho CY, Day SM, Ashley EA, Michels M, Pereira AC, Jacoby D, et al.; SHaRe Investigators. Genotype and lifetime burden of disease in hypertrophic cardiomyopathy: Insights from the Sarcomeric Human Cardiomyopathy Registry (SHaRe). Circulation 2018;138:1387-1398. https://doi.org/10.1161/CIRCULATIONAHA.117.033200
Liu Q, Li D, Berger AE, Johns RA, Gao L. Survival and prognostic factors in hypertrophic cardiomyopathy: A meta-analysis. Sci Rep 2017;7:11957. https://doi.org/10.1038/s41598-017-12289-4
Marstrand P, Han L, Day SM, Olivotto I, Ashley EA, Michels M, et al.; SHaRe Investigators. Hypertrophic cardiomyopathy with left ventricular systolic dysfunction: Insights from the SHaRe registry. Circulation 2020;141:1371-1383. https://doi.org/10.1161/CIRCULATIONAHA.119.044366
Ommen SR, Mital S, Burke MA, Day SM, Deswal A, Elliott P, et al. 2020 AHA/ACC Guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: A report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol 2020;76:e159-e240. https://doi.org/10.1016/j.jacc.2020.08.045
Sherrid MV, Shetty A, Winson G, Kim B, Musat D, Alviar CL, et al. Treatment of obstructive hypertrophic cardiomyopathy symptoms and gradient resistant to first-line therapy with β-blockade or verapamil. Circ Heart Fail 2013;6:694-702. https://doi.org/10.1161/CIRCHEARTFAILURE.112.000122
Spoladore R, Maron MS, D'Amato R, Camici PG, Olivotto I. Pharmacological treatment options for hypertrophic cardiomyopathy: High time for evidence. Eur Heart J 2012;33:1724-1733. https://doi.org/10.1093/eurheartj/ehs150
Ho CY, Day SM, Axelsson A, Russell MW, Zahka K, Lever HM, et al.; VANISH Investigators. Valsartan in early-stage hypertrophic cardiomyopathy: A randomized phase 2 trial. Nat Med 2021;27:1818-1824. https://doi.org/10.1038/s41591-021-01505-4
Patel SR, Saeed O, Naftel D, Myers S, Kirklin J, Jorde UP, et al. Outcomes of restrictive and hypertrophic cardiomyopathies after LVAD: An INTERMACS analysis. J Card Fail 2017;23:859-867. https://doi.org/10.1016/j.cardfail.2017.09.011
Hang D, Nguyen A, Schaff HV. Surgical treatment for hypertrophic cardiomyopathy: A historical perspective. Ann Cardiothorac Surg 2017;6:318-328. https://doi.org/10.21037/acs.2017.04.03
Stefàno P, Argirò A, Bacchi B, Iannone L, Bertini A, Zampieri M, et al. Does a standard myectomy exist for obstructive hypertrophic cardiomyopathy? From the Morrow variations to precision surgery. Int J Cardiol 2023;371:278-286. https://doi.org/10.1016/j.ijcard.2022.09.036
Liebregts M, Vriesendorp PA, Mahmoodi BK, Schinkel AF, Michels M, ten Berg JM. A systematic review and meta-analysis of long-term outcomes after septal reduction therapy in patients with hypertrophic cardiomyopathy. JACC Heart Fail 2015;3:896-905. https://doi.org/10.1016/j.jchf.2015.06.011
Toepfer CN, Garfinkel AC, Venturini G, Wakimoto H, Repetti G, Alamo L, et al. Myosin sequestration regulates sarcomere function, cardiomyocyte energetics, and metabolism, informing the pathogenesis of hypertrophic cardiomyopathy. Circulation 2020;141:828-842. https://doi.org/10.1161/CIRCULATIONAHA.119.042339
Heitner SB, Jacoby D, Lester SJ, Owens A, Wang A, Zhang D, et al. Mavacamten treatment for obstructive hypertrophic cardiomyopathy: A clinical trial. Ann Intern Med 2019;170:741-748. https://doi.org/10.7326/M18-3016
Olivotto I, Oreziak A, Barriales-Villa R, Abraham TP, Masri A, Garcia-Pavia P, et al.; EXPLORER-HCM Study Investigators. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2020;396:759-769. https://doi.org/10.1016/S0140-6736(20)31792-X
Hegde SM, Lester SJ, Solomon SD, Michels M, Elliott PM, Nagueh SF, et al. Effect of mavacamten on echocardiographic features in symptomatic patients with obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol 2021;78:2518-2532. https://doi.org/10.1016/j.jacc.2021.09.1381
Rader F, Choudhury L, Saberi S, Fermin D, Wheeler MT, Abraham TP, et al. Long-term safety of mavacamten in patients with obstructive hypertrophic cardiomyopathy: Interim results of the MAVA-Long Term Extension (LTE) study. J Am Coll Cardiol 2021;77:532 (abstr). https://doi.org/10.1016/S0735-1097(21)01891-X
Desai MY, Owens A, Geske JB, Wolski K, Naidu SS, Smedira NG, et al. Myosin inhibition in patients with obstructive hypertrophic cardiomyopathy referred for septal reduction therapy. J Am Coll Cardiol 2022;80:95-108. https://doi.org/10.1016/j.jacc.2022.04.048
Morelli C, Ingrasciotta G, Jacoby D, Masri A, Olivotto I. Sarcomere protein modulation: The new frontier in cardiovascular medicine and beyond. Eur J Intern Med 2022;102:1-7. https://doi.org/10.1016/j.ejim.2022.04.020
Zeppenfeld K, Tfelt-Hansen J, de Riva M, Winkel BG, Behr ER, Blom NA, et al.; ESC Scientific Document Group. 2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Eur Heart J 2022;43:3997-4126. https://doi.org/10.1093/eurheartj/ehac262
Norrish G, Qu C, Field E, Cervi E, Khraiche D, Klaassen S, et al. External validation of the HCM Risk-Kids model for predicting sudden cardiac death in childhood hypertrophic cardiomyopathy. Eur J Prev Cardiol 2022;29:678-686. https://doi.org/10.1093/eurjpc/zwab181
Connolly SJ, Dorian P, Roberts RS, Gent M, Bailin S, Fain ES, et al.; Optimal Pharmacological Therapy in Cardioverter Defibrillator Patients (OPTIC) Investigators. Comparison of β-blockers, amiodarone plus β-blockers, or sotalol for prevention of shocks from implantable cardioverter defibrillators: The OPTIC study: A randomized trial. JAMA 2006;295:165-171. https://doi.org/10.1001/jama.295.2.165
Igarashi M, Nogami A, Kurosaki K, Hanaki Y, Komatsu Y, Fukamizu S, et al. Radiofrequency catheter ablation of ventricular tachycardia in patients with hypertrophic cardiomyopathy and apical aneurysm. JACC Clin Electrophysiol 2018;4:339-350. https://doi.org/10.1016/j.jacep.2017.12.020
Santangeli P, Di Biase L, Lakkireddy D, Burkhardt JD, Pillarisetti J, Michowitz Y, et al. Radiofrequency catheter ablation of ventricular arrhythmias in patients with hypertrophic cardiomyopathy: Safety and feasibility. Heart Rhythm 2010;7:1036-1042. https://doi.org/10.1016/j.hrthm.2010.05.022
Guttmann OP, Rahman MS, O'Mahony C, Anastasakis A, Elliott PM. Atrial fibrillation and thromboembolism in patients with hypertrophic cardiomyopathy: Systematic review. Heart 2014;100:465-472. https://doi.org/10.1136/heartjnl-2013-304276
Guttmann OP, Pavlou M, O'Mahony C, Monserrat L, Anastasakis A, Rapezzi C, et al.; Hypertrophic Cardiomyopathy Outcomes Investigators. Prediction of thrombo-embolic risk in patients with hypertrophic cardiomyopathy (HCM Risk-CVA). Eur J Heart Fail 2015;17:837-845. https://doi.org/10.1002/ejhf.316
Hayashi H, Iwasaki YK, Arai T, Mimuro R, Hachisuka M, Maru Y, et al. Prognostic impact of newly detected atrial fibrillation in patients with hypertrophic cardiomyopathy following cardiac implantable electronic device implantation. Heart Vessels 2021;36:667-674. https://doi.org/10.1007/s00380-020-01728-4
Mahajan R, Perera T, Elliott AD, Twomey DJ, Kumar S, Munwar DA, et al. Subclinical device-detected atrial fibrillation and stroke risk: A systematic review and meta-analysis. Eur Heart J 2018;39:1407-1415. https://doi.org/10.1093/eurheartj/ehx731
Providencia R, Elliott P, Patel K, McCready J, Babu G, Srinivasan N, et al. Catheter ablation for atrial fibrillation in hypertrophic cardiomyopathy: A systematic review and meta-analysis. Heart 2016;102:1533-1543. https://doi.org/10.1136/heartjnl-2016-309406
Creta A, Elliott P, Earley MJ, Dhinoja M, Finlay M, Sporton S, et al. Catheter ablation of atrial fibrillation in patients with hypertrophic cardiomyopathy: A European observational multicentre study. Europace 2021;23:1409-1417. https://doi.org/10.1093/europace/euab022
Rapezzi C, Aimo A, Barison A, Emdin M, Porcari A, Linhart A, et al. Restrictive cardiomyopathy: Definition and diagnosis. Eur Heart J 2022;43:4679-4693. https://doi.org/10.1093/eurheartj/ehac543
Donnellan E, Elshazly MB, Vakamudi S, Wazni OM, Cohen JA, Kanj M, et al. No association between CHADS-VASc score and left atrial appendage thrombus in patients with transthyretin amyloidosis. JACC Clin Electrophysiol 2019;5:1473-1474. https://doi.org/10.1016/j.jacep.2019.10.013
Cappelli F, Tini G, Russo D, Emdin M, Del Franco A, Vergaro G, et al. Arterial thrombo-embolic events in cardiac amyloidosis: A look beyond atrial fibrillation. Amyloid 2021;28:12-18. https://doi.org/10.1080/13506129.2020.1798922
Pereira NL, Grogan M, Dec GW. Spectrum of restrictive and infiltrative cardiomyopathies: Part 1 of a 2-part series. J Am Coll Cardiol 2018;71:1130-1148. https://doi.org/10.1016/j.jacc.2018.01.016
Arbustini E, Morbini P, Grasso M, Fasani R, Verga L, Bellini O, et al. Restrictive cardiomyopathy, atrioventricular block and mild to subclinical myopathy in patients with desmin-immunoreactive material deposits. J Am Coll Cardiol 1998;31:645-653. https://doi.org/10.1016/s0735-1097(98)00026-6
Heidenreich PA, Hancock SL, Lee BK, Mariscal CS, Schnittger I. Asymptomatic cardiac disease following mediastinal irradiation. J Am Coll Cardiol 2003;42:743-749. https://doi.org/10.1016/s0735-1097(03)00759-9
Chello M, Mastroroberto P, Romano R, Zofrea S, Bevacqua I, Marchese AR. Changes in the proportion of types I and III collagen in the left ventricular wall of patients with post-irradiative pericarditis. Cardiovasc Surg 1996;4:222-226. https://doi.org/10.1016/0967-2109(96)82320-9
González-López E, Gallego-Delgado M, Guzzo-Merello G, de Haro-Del Moral FJ, Cobo-Marcos M, Robles C, et al. Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. Eur Heart J 2015;36:2585-2594. https://doi.org/10.1093/eurheartj/ehv338
Falk RH, Alexander KM, Liao R, Dorbala S. AL (light-chain) cardiac amyloidosis: A review of diagnosis and therapy. J Am Coll Cardiol 2016;68:1323-1341. https://doi.org/10.1016/j.jacc.2016.06.053
Adams D, Gonzalez-Duarte A, O'Riordan WD, Yang CC, Ueda M, Kristen AV, et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N Engl J Med 2018;379:11-21. https://doi.org/10.1056/NEJMoa1716153
Benson MD, Waddington-Cruz M, Berk JL, Polydefkis M, Dyck PJ, Wang AK, et al. Inotersen treatment for patients with hereditary transthyretin amyloidosis. N Engl J Med 2018;379:22-31. https://doi.org/10.1056/NEJMoa1716793
Gillmore JD, Gane E, Taubel J, Kao J, Fontana M, Maitland ML, et al. CRISPR-Cas9 in vivo gene editing for transthyretin amyloidosis. N Engl J Med 2021;385:493-502. https://doi.org/10.1056/NEJMoa2107454
Maurer MS, Schwartz JH, Gundapaneni B, Elliott PM, Merlini G, Waddington-Cruz M, et al.; ATTR-ACT Study Investigators. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med 2018;379:1007-1016. https://doi.org/10.1056/NEJMoa1805689
Elliott P, Drachman BM, Gottlieb SS, Hoffman JE, Hummel SL, Lenihan DJ, et al. Long-term survival with tafamidis in patients with transthyretin amyloid cardiomyopathy. Circ Heart Fail 2022;15:e008193. https://doi.org/10.1161/CIRCHEARTFAILURE.120.008193
Yilmaz A, Bauersachs J, Bengel F, Büchel R, Kindermann I, Klingel K, et al. Diagnosis and treatment of cardiac amyloidosis: Position statement of the German Cardiac Society (DGK). Clin Res Cardiol 2021;110:479-506. https://doi.org/10.1007/s00392-020-01799-3
Garcia-Pavia P, Rapezzi C, Adler Y, Arad M, Basso C, Brucato A, et al. Diagnosis and treatment of cardiac amyloidosis. A position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur J Heart Fail 2021;23:512-526. https://doi.org/10.1002/ejhf.2140
Kittleson MM, Maurer MS, Ambardekar AV, Bullock-Palmer RP, Chang PP, Eisen HJ, et al.; American Heart Association Heart Failure and Transplantation Committee of the Council on Clinical Cardiology. Cardiac amyloidosis: Evolving diagnosis and management: A scientific statement from the American Heart Association. Circulation 2020;142:e7-e22. https://doi.org/10.1161/CIR.0000000000000792
Kitaoka H, Izumi C, Izumiya Y, Inomata T, Ueda M, Kubo T, et al.; Japanese Circulation Society Joint Working Group. JCS 2020 Guideline on diagnosis and treatment of cardiac amyloidosis. Circ J 2020;84:1610-1671. https://doi.org/10.1253/circj.CJ-20-0110
Fine NM, Davis MK, Anderson K, Delgado DH, Giraldeau G, Kitchlu A, et al. Canadian Cardiovascular Society/Canadian Heart Failure Society joint position statement on the evaluation and management of patients with cardiac amyloidosis. Can J Cardiol 2020;36:322-334. https://doi.org/10.1016/j.cjca.2019.12.034
Aimo A, Rapezzi C, Vergaro G, Giannoni A, Spini V, Passino C, et al. Management of complications of cardiac amyloidosis: 10 questions and answers. Eur J Prev Cardiol 2021;28:1000-1005. https://doi.org/10.1177/2047487320920756
Patel MR, Cawley PJ, Heitner JF, Klem I, Parker MA, Jaroudi WA, et al. Detection of myocardial damage in patients with sarcoidosis. Circulation 2009;120:1969-1977. https://doi.org/10.1161/CIRCULATIONAHA.109.851352
Baughman RP, Teirstein AS, Judson MA, Rossman MD, Yeager H Jr, Bresnitz EA, et al.; Case Control Etiologic Study of Sarcoidosis (ACCESS) Research Group. Clinical characteristics of patients in a case control study of sarcoidosis. Am J Respir Crit Care Med 2001;164:1885-1889. https://doi.org/10.1164/ajrccm.164.10.2104046
Trivieri MG, Spagnolo P, Birnie D, Liu P, Drake W, Kovacic JC, et al. Challenges in cardiac and pulmonary sarcoidosis: JACC state-of-the-art review. J Am Coll Cardiol 2020;76:1878-1901. https://doi.org/10.1016/j.jacc.2020.08.042
Baughman RP, Valeyre D, Korsten P, Mathioudakis AG, Wuyts WA, Wells A, et al. ERS clinical practice guidelines on treatment of sarcoidosis. Eur Respir J 2021;58:2004079. https://doi.org/10.1183/13993003.04079-2020
Yazaki Y, Isobe M, Hiroe M, Morimoto S, Hiramitsu S, Nakano T, et al. Prognostic determinants of long-term survival in Japanese patients with cardiac sarcoidosis treated with prednisone. Am J Cardiol 2001;88:1006-1010. https://doi.org/10.1016/s0002-9149(01)01978-6
Padala SK, Peaslee S, Sidhu MS, Steckman DA, Judson MA. Impact of early initiation of corticosteroid therapy on cardiac function and rhythm in patients with cardiac sarcoidosis. Int J Cardiol 2017;227:565-570. https://doi.org/10.1016/j.ijcard.2016.10.101
Kato Y, Morimoto S, Uemura A, Hiramitsu S, Ito T, Hishida H. Efficacy of corticosteroids in sarcoidosis presenting with atrioventricular block. Sarcoidosis Vasc Diffuse Lung Dis 2003;20(2):133-7. PMID: 12870723.
Birnie D, Beanlands RSB, Nery P, Aaron SD, Culver DA, DeKemp RA, et al. Cardiac sarcoidosis multi-center randomized controlled trial (CHASM CS- RCT). Am Heart J 2020;220:246-252. https://doi.org/10.1016/j.ahj.2019.10.003
Kandolin R, Lehtonen J, Airaksinen J, Vihinen T, Miettinen H, Ylitalo K, et al. Cardiac sarcoidosis: Epidemiology, characteristics, and outcome over 25 years in a nationwide study. Circulation 2015;131:624-632. https://doi.org/10.1161/CIRCULATIONAHA.114.011522
Nordenswan HK, Pöyhönen P, Lehtonen J, Ekström K, Uusitalo V, Niemelä M, et al. Incidence of sudden cardiac death and life-threatening arrhythmias in clinically manifest cardiac sarcoidosis with and without current indications for an implantable cardioverter defibrillator. Circulation 2022;146:964-975. https://doi.org/10.1161/CIRCULATIONAHA.121.058120
Sweet ME, Mestroni L, Taylor MRG. Genetic infiltrative cardiomyopathies. Heart Fail Clin 2018;14:215-224. https://doi.org/10.1016/j.hfc.2017.12.003
Ortiz A, Germain DP, Desnick RJ, Politei J, Mauer M, Burlina A, et al. Fabry disease revisited: Management and treatment recommendations for adult patients. Mol Genet Metab 2018;123:416-427. https://doi.org/10.1016/j.ymgme.2018.02.014
Hughes DA, Nicholls K, Shankar SP, Sunder-Plassmann G, Koeller D, Nedd K, et al. Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT study. J Med Genet 2017;54:288-296. https://doi.org/10.1136/jmedgenet-2016-104178
Welford RWD, Mühlemann A, Garzotti M, Rickert V, Groenen PMA, Morand O, et al. Glucosylceramide synthase inhibition with lucerastat lowers globotriaosylceramide and lysosome staining in cultured fibroblasts from Fabry patients with different mutation types. Hum Mol Genet 2018;27:3392-3403. https://doi.org/10.1093/hmg/ddy248
Guérard N, Morand O, Dingemanse J. Lucerastat, an iminosugar with potential as substrate reduction therapy for glycolipid storage disorders: Safety, tolerability, and pharmacokinetics in healthy subjects. Orphanet J Rare Dis 2017;12:9. https://doi.org/10.1186/s13023-017-0565-9
Schoser B, Stewart A, Kanters S, Hamed A, Jansen J, Chan K, et al. Survival and long-term outcomes in late-onset Pompe disease following alglucosidase alfa treatment: A systematic review and meta-analysis. J Neurol 2017;264:621-630. https://doi.org/10.1007/s00415-016-8219-8
Joanne M, Skye N, Tracy M. The effectiveness of enzyme replacement therapy for juvenile-onset Pompe disease: A systematic review. J Inherit Metab Dis 2019;42:57-65. https://doi.org/10.1002/jimd.12027
Aldenhoven M, Wynn RF, Orchard PJ, O'Meara A, Veys P, Fischer A, et al. Long-term outcome of Hurler syndrome patients after hematopoietic cell transplantation: An international multicenter study. Blood 2015;125:2164-2172. https://doi.org/10.1182/blood-2014-11-608075
Elsayed ME, Sharif MU, Stack AG. Transferrin saturation: A body iron biomarker. Adv Clin Chem 2016;75:71-97. https://doi.org/10.1016/bs.acc.2016.03.002
Lota AS, Gatehouse PD, Mohiaddin RH. T2 mapping and T2* imaging in heart failure. Heart Fail Rev 2017;22:431-440. https://doi.org/10.1007/s10741-017-9616-5
Murphree CR, Nguyen NN, Raghunathan V, Olson SR, DeLoughery T, Shatzel JJ. Diagnosis and management of hereditary haemochromatosis. Vox Sang 2020;115:255-262. https://doi.org/10.1111/vox.12896
Sliwa K. Heart failure can affect everyone: The ESC Geoffrey Rose lecture. Eur Heart J 2020;41:1298-1306. https://doi.org/10.1093/eurheartj/ehaa084
Pereira NL, Grogan M, Dec GW. Spectrum of restrictive and infiltrative cardiomyopathies: Part 2 of a 2-part series. J Am Coll Cardiol 2018;71:1149-1166. https://doi.org/10.1016/j.jacc.2018.01.017
Helbig G. Imatinib for the treatment of hypereosinophilic syndromes. Expert Rev Clin Immunol 2018;14:163-170. https://doi.org/10.1080/1744666X.2018.1425142
Butterfield JH, Weiler CR. Treatment of hypereosinophilic syndromes - the first 100 years. Semin Hematol 2012;49:182-191. https://doi.org/10.1053/j.seminhematol.2012.01.001
Corrado D, Link MS, Calkins H. Arrhythmogenic right ventricular cardiomyopathy. N Engl J Med 2017;376:61-72. https://doi.org/10.1056/NEJMra1509267
Corrado D, Basso C, Judge DP. Arrhythmogenic cardiomyopathy. Circ Res 2017;121:784-802. https://doi.org/10.1161/CIRCRESAHA.117.309345
Corrado D, van Tintelen PJ, McKenna WJ, Hauer RNW, Anastastakis A, Asimaki A, et al. Arrhythmogenic right ventricular cardiomyopathy: Evaluation of the current diagnostic criteria and differential diagnosis. Eur Heart J 2020;41:1414-1429. https://doi.org/10.1093/eurheartj/ehz669
Corrado D, Perazzolo Marra M, Zorzi A, Beffagna G, Cipriani A, Lazzari M, et al. Diagnosis of arrhythmogenic cardiomyopathy: The Padua criteria. Int J Cardiol 2020;319:106-114. https://doi.org/10.1016/j.ijcard.2020.06.005
Akdis D, Brunckhorst C, Duru F, Saguner AM. Arrhythmogenic cardiomyopathy: Electrical and structural phenotypes. Arrhythm Electrophysiol Rev 2016;5:90-101. https://doi.org/10.15420/AER.2016.4.3
James CA, Jongbloed JDH, Hershberger RE, Morales A, Judge DP, Syrris P, et al. International evidence based reappraisal of genes associated with arrhythmogenic right ventricular cardiomyopathy using the Clinical Genome Resource framework. Circ Genom Precis Med 2021;14:e003273. https://doi.org/10.1161/CIRCGEN.120.003273
Sepehrkhouy S, Gho J, van Es R, Harakalova M, de Jonge N, Dooijes D, et al. Distinct fibrosis pattern in desmosomal and phospholamban mutation carriers in hereditary cardiomyopathies. Heart Rhythm 2017;14:1024-1032. https://doi.org/10.1016/j.hrthm.2017.03.034
Quarta G, Muir A, Pantazis A, Syrris P, Gehmlich K, Garcia-Pavia P, et al. Familial evaluation in arrhythmogenic right ventricular cardiomyopathy. Circulation 2011;123:2701-2709. https://doi.org/10.1161/CIRCULATIONAHA.110.976936
Corrado D, Wichter T, Link MS, Hauer R, Marchlinski F, Anastasakis A, et al. Treatment of arrhythmogenic right ventricular cardiomyopathy/dysplasia: An international task force consensus statement. Eur Heart J 2015;36:3227-3237. https://doi.org/10.1093/eurheartj/ehv162
Calkins H, Corrado D, Marcus F. Risk stratification in arrhythmogenic right ventricular cardiomyopathy. Circulation 2017;136:2068-2082. https://doi.org/10.1161/CIRCULATIONAHA.117.030792
Corrado D, Basso C. Arrhythmogenic left ventricular cardiomyopathy. Heart 2022;108:733-743. https://doi.org/10.1136/heartjnl-2020-316944
Verstraelen TE, van Lint FHM, Bosman LP, de Brouwer R, Proost VM, Abeln BGS, et al. Prediction of ventricular arrhythmia in phospholamban p.Arg14del mutation carriers - reaching the frontiers of individual risk prediction. Eur Heart J 2021;42:2842-2850. https://doi.org/10.1093/eurheartj/ehab294
Corrado D, Migliore F, Zorzi A. Arrhythmic risk stratification in arrhythmogenic cardiomyopathy: New predictors for left-sided variants? Eur Heart J 2021;42:2851-2853. https://doi.org/10.1093/eurheartj/ehab355
Corrado D, Leoni L, Link MS, Della Bella P, Gaita F, Curnis A, et al. Implantable cardioverter-defibrillator therapy for prevention of sudden death in patients with arrhythmogenic right ventricular cardiomyopathy/dysplasia. Circulation 2003;108:3084-3091. https://doi.org/10.1161/01.CIR.0000103130.33451.D2
Corrado D, Calkins H, Link MS, Leoni L, Favale S, Bevilacqua M, et al. Prophylactic implantable defibrillator in patients with arrhythmogenic right ventricular cardiomyopathy/dysplasia and no prior ventricular fibrillation or sustained ventricular tachycardia. Circulation 2010;122:1144-1152. https://doi.org/10.1161/CIRCULATIONAHA.109.913871
Bhonsale A, James CA, Tichnell C, Murray B, Gagarin D, Philips B, et al. Incidence and predictors of implantable cardioverter-defibrillator therapy in patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy undergoing implantable cardioverter-defibrillator implantation for primary prevention. J Am Coll Cardiol 2011;58:1485-1496. https://doi.org/10.1016/j.jacc.2011.06.043
Mazzanti A, Ng K, Faragli A, Maragna R, Chiodaroli E, Orphanou N, et al. Arrhythmogenic right ventricular cardiomyopathy: Clinical course and predictors of arrhythmic risk. J Am Coll Cardiol 2016;68:2540-2550. https://doi.org/10.1016/j.jacc.2016.09.951
Saguner AM, Vecchiati A, Baldinger SH, Rüeger S, Medeiros-Domingo A, Mueller-Burri AS, et al. Different prognostic value of functional right ventricular parameters in arrhythmogenic right ventricular cardiomyopathy/dysplasia. Circ Cardiovasc Imaging 2014;7:230-239. https://doi.org/10.1161/CIRCIMAGING.113.000210
Agbaedeng TA, Roberts KA, Colley L, Noubiap JJ, Oxborough D. Incidence and predictors of sudden cardiac death in arrhythmogenic right ventricular cardiomyopathy: A pooled analysis. Europace 2022;24:1665-1674. https://doi.org/10.1093/europace/euac014
Cadrin-Tourigny J, Bosman LP, Wang W, Tadros R, Bhonsale A, Bourfiss M, et al. Sudden cardiac death prediction in arrhythmogenic right ventricular cardiomyopathy: A multinational collaboration. Circ Arrhythm Electrophysiol 2021;14:e008509. https://doi.org/10.1161/CIRCEP.120.008509
Cadrin-Tourigny J, Bosman LP, Nozza A, Wang W, Tadros R, Bhonsale A, et al. A new prediction model for ventricular arrhythmias in arrhythmogenic right ventricular cardiomyopathy. Eur Heart J 2019;40:1850-1858. https://doi.org/10.1093/eurheartj/ehz103
Corrado D, Link MS, Schwartz PJ. Implantable defibrillators in primary prevention of genetic arrhythmias. A shocking choice? Eur Heart J 2022;43:3029-3040. https://doi.org/10.1093/eurheartj/ehac298
Jordà P, Bosman LP, Gasperetti A, Mazzanti A, Gourraud JB, Davies B, et al. Arrhythmic risk prediction in arrhythmogenic right ventricular cardiomyopathy: External validation of the arrhythmogenic right ventricular cardiomyopathy risk calculator. Eur Heart J 2022;43:3041-3052. https://doi.org/10.1093/eurheartj/ehac289
Protonotarios A, Bariani R, Cappelletto C, Pavlou M, García-García A, Cipriani A, et al. Importance of genotype for risk stratification in arrhythmogenic right ventricular cardiomyopathy using the 2019 ARVC risk calculator. Eur Heart J 2022;43:3053-3067. https://doi.org/10.1093/eurheartj/ehac235
Mahida S, Venlet J, Saguner AM, Kumar S, Baldinger SH, AbdelWahab A, et al. Ablation compared with drug therapy for recurrent ventricular tachycardia in arrhythmogenic right ventricular cardiomyopathy: Results from a multicenter study. Heart Rhythm 2019;16:536-543. https://doi.org/10.1016/j.hrthm.2018.10.016
Masri A, Sherrid MV, Choudhury L, Rader F, Kramer CM, Saberi S, et al. Aficamten in patients with symptomatic non-obstructive hypertrophic cardiomyopathy (REDWOOD-HCM Cohort 4). J Am Coll Cardiol 2023;81:609 (abstr). https://doi.org/10.1016/S0735-1097(23)01053-7
Richards DB, Cookson LM, Berges AC, Barton SV, Lane T, Ritter JM, et al. Therapeutic clearance of amyloid by antibodies to serum amyloid P component. N Engl J Med 2015;373:1106-1114. https://doi.org/10.1056/NEJMoa1504942
Saelices L, Chung K, Lee JH, Cohn W, Whitelegge JP, Benson MD, et al. Amyloid seeding of transthyretin by ex vivo cardiac fibrils and its inhibition. Proc Natl Acad Sci U S A 2018;115:E6741-e50. https://doi.org/10.1073/pnas.1805131115
Garcia-Pavia P, aus dem Siepen F, Donal E, Lairez O, van der Meer P, Kristen AV, et al. Phase 1 trial of antibody NI006 for depletion of cardiac transthyretin amyloid. N Engl J Med 2023;389:239-250. https://doi.org/10.1056/NEJMoa2303765
Rossano J, Taylor M, Lin K, Epstein S, Battiprolu P, Ricks D, et al. Phase 1 Danon disease results: The first single dose intravenous (IV) gene therapy (RP-A501) with recombinant adeno-associated virus (AAV9:LAMP2B) for a monogenic cardiomyopathy. Circulation 2022;146:A11117 (abstr). https://doi.org/10.1161/circ.146.suppl_1.11117
Padrón-Barthe L, Villalba-Orero M, Gómez-Salinero JM, Domínguez F, Román M, Larrasa-Alonso J, et al. Severe cardiac dysfunction and death caused by arrhythmogenic right ventricular cardiomyopathy type 5 are improved by inhibition of glycogen synthase kinase-3β. Circulation 2019;140:1188-1204. https://doi.org/10.1161/CIRCULATIONAHA.119.040366
Karakikes I, Stillitano F, Nonnenmacher M, Tzimas C, Sanoudou D, Termglinchan V, et al. Correction of human phospholamban R14del mutation associated with cardiomyopathy using targeted nucleases and combination therapy. Nat Commun 2015;6:6955. https://doi.org/10.1038/ncomms7955
Tharp C, Mestroni L, Taylor M. Modifications of titin contribute to the progression of cardiomyopathy and represent a therapeutic target for treatment of heart failure. J Clin Med 2020;9:2770. https://doi.org/10.3390/jcm9092770
Brauch KM, Karst ML, Herron KJ, de Andrade M, Pellikka PA, Rodeheffer RJ, et al. Mutations in ribonucleic acid binding protein gene cause familial dilated cardiomyopathy. J Am Coll Cardiol 2009;54:930-941. https://doi.org/10.1016/j.jacc.2009.05.038
Verdonschot JAJ, Hazebroek MR, Derks KWJ, Barandiaran Aizpurua A, Merken JJ, Wang P, et al. Titin cardiomyopathy leads to altered mitochondrial energetics, increased fibrosis and long-term life-threatening arrhythmias. Eur Heart J 2018;39:864-873. https://doi.org/10.1093/eurheartj/ehx808
Gerbino A, Procino G, Svelto M, Carmosino M. Role of lamin A/C gene mutations in the signaling defects leading to cardiomyopathies. Front Physiol 2018;9:1356. https://doi.org/10.3389/fphys.2018.01356
Verdonschot JAJ, Hazebroek MR, Ware JS, Prasad SK, Heymans SRB. Role of targeted therapy in dilated cardiomyopathy: The challenging road toward a personalized approach. J Am Heart Assoc 2019;8:e012514. https://doi.org/10.1161/JAHA.119.012514